ClinicalTrials.gg
Status unknownNCT05823883Updated May 26, 2023

This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component in Healthy Adult Volunteers in Fed Condition.

A Phase 1 interventional study of DW6014 in DW6014, sponsored by Dong Wha Pharmaceutical Co. Ltd.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-26.

Sponsored by Dong Wha Pharmaceutical Co. Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6014 and each component in healthy adult volunteers in fed condition.

Read the detailed description

This is a Phase 1, randomized, open-label, Oral, Single-dose, two-way crossover study in healthy subjects.

02

Conditions studied

  • DW6014
03

In context

Lead sponsor

Dong Wha Pharmaceutical Co. Ltd. is the lead sponsor of 18 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects aged up to 19 years
  • Subjects weighing at least 50.0 kg with a between 18.0 kg/m2 and 30.0 kg/m2
  • Subjects with neither congenital nor chronic diseases requiring treatment, and no abnormal symptoms or findings upon medical examination
  • Subjects considered eligible for the study participation in accordance to the results of clinical laboratory tests, vital signs, physical examinations and 12-lead conducted at the time of screening, based on the product (IP) characteristics
  • Subjects who has a full understanding in participation of the study, voluntarily provide a written consent in participation, and give full agreement in following the subject guidelines throughout the entire study period

Exclusion criteria

Exclusion Criteria:

  • Subjects with any hepatic, renal, nervous, respiratory, endocrine, circulatory, tumor, genitourinary, cardiovascular, digestive, musculoskeletal systemic diseases or other medical history
  • Subject with galactose intolerance, Lapp lactase deficience, glucose-galactose malabsorption or other genetic problem
  • Subject following gastrointestinal diseases or gastrointestinal surgery that may affect the absorption of the IP
  • Pregnant subjects with a positive urine HCG(human chorionic gonadotropin) test, or lactating female subjects
  • Subject with a medical history of reactions (anaphylaxis or antibiotics etc.) to containing empagliflozin and metformin components, formulation additives, and other drugs (aspirin, antibiotics, biguanide drugs, etc.) or clinically significant hypersensitivity reactions
  • Subjects with clinically significant 12-lead findings at the time of screening
  • Subjects with a past history of drug abuse or a positive urine drug test
  • Subjects with SBP(systolic blood pressure) ≥ 150 mmHg or ≤ 90 mmHg; DBP(diastolic blood pressure) ≥ 100 mmHg or ≤ 60 mmHg; Pulse Rate ≤ 40 bpm or ≥ 100 bpm at the time of screening
  • Subjects taking drugs known to significantly induce or inhibit drug metabolizing enzymes, including barbitals within 1 months prior to the first IP administration
  • Subjects who have administered any prescription drugs or herbal medicines that may affect the characteristics of clinical drugs within 2 weeks prior to the first administration date, or have administered any over-the-counter (OTC) or vitamin preparations within 10 days
  • Subjects taking drugs known to significantly induce or inhibit drug metabolizing enzymes, including barbitals within 1 months prior to the first IP administration
  • Subjects who have participated and were given any other study drugs in other clinical study within 6 months prior to the first IP administration Before the first administration date whole blood donation within 2 months or component blood donation within 1 month or received a blood transfusion within 1 month, or the subject who cannot forbid transfusion from the time of obtaining ICF( form) until PSV(post-study visit)
  • Subjects who have consistently drunk alcohol within 6 months
  • Subjects who have smoked more than 10 cigarettes/day on average
  • Subjects who have eaten or cannot refrain from eating grapefruit (grapefruit)-containing food from 48 hours before the first administration until the time of PSV(post-study visit)
  • Subjects who have consumed or cannot refrain from consuming caffeine-containing food during the period from 24 hours prior to administration of each period to the time of the last blood sampling
  • Subjects who have done and are unable to refrain from strenuous activity
  • Subjects who are planning for pregnancy or not willing to use a medically reliable forms of
  • Subjects otherwise considered ineligible for participation due to other reasons including clinical laboratory test results not mentioned in the inclusion/exclusion criteria at the investigator's discretion
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Sequence A

    Period 1: Empagliflozin and Metformin Period 2: DW6014

    Drug: DW6014

  • Experimental
    Sequence B

    Period 1: DW6014 Period 2: Empagliflozin and Metformin

    Drug: DW6014

Interventions

  • DrugDW6014

    Drug pages: Empagliflozin · Metformin

    Drug: DW6014 Single oral administration of DW6014 in fed condition Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition

    Also known as: Empagliflozin and Metformin

06

What researchers measure

Primary outcomes

  1. AUC0-t

    AUC0-t of Metformin

    Time frame: 48 hour

  2. Cmax

    Cmax of Metformin

    Time frame: 48 hour

Secondary outcomes

  1. Tmax

    Tmax of Metformin

    Time frame: 48 hour

  2. AUCinf

    AUCinf of Metformin

    Time frame: 48 hour

  3. t1/2

    t1/2 of Metformin

    Time frame: 48 hour

  4. CL/F

    CL/F of Metformin

    Time frame: 48 hour

  5. Vd/F

    Vd/F of Metformin

    Time frame: 48 hour

07

Study locations

1 site
  • Chungbuk National University Hospital
    Cheongju-si, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2023; primary completion for Jul 2023, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2023
First posted
Apr 21, 2023
StartEst.
Jun 2023
Primary completionEst.
Jul 2023
CompletionEst.
Aug 2023
Last update
May 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05823883
Lead sponsor
Dong Wha Pharmaceutical Co. Ltd.
Responsible party
Sponsor
First posted
Apr 21, 2023
Start date
Jun 2023 (estimated)
Primary completion
Jul 2023 (estimated)
Completion
Aug 2023 (estimated)
Last update
May 26, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Metformin

Start the discussion